Australia is currently observing the arrival of retatrutide, a novel dual GIP and GLP-1 receptor medication , representing a potential advance in obesity treatment . Early research findings have demonstrated https://giant-bike731144.yourkwikimage.com/2775227/emerging_medication_in_australia_a_promising_solution_for_obesity_management